Rossi Tania, Gallerani Giulia, Martinelli Giovanni, Maltoni Roberta, Fabbri Francesco
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Scientific Directorate, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Biomedicines. 2021 Sep 16;9(9):1242. doi: 10.3390/biomedicines9091242.
Breast cancer (BC) is a disease characterized by high degrees of heterogeneity at morphologic, genomic, and genetic levels, even within the same tumor mass or among patients. As a consequence, different subpopulations coexist and less represented clones may have a selective advantage, significantly influencing the outcome of BC patients. Circulating tumor cells (CTCs) represent a rare population of cells with a crucial role in metastatic cascade, and in recent years have represented a fascinating alternative to overcome the heterogeneity issue as a "liquid biopsy". However, besides the raw enumeration of these cells in advanced epithelial tumors, there are no CTC-based assays applied in the clinical practice to improve personalized medicine. In this review, we report the latest findings in the field of CTCs for intra-tumoral heterogeneity unmasking in BC, supporting the need to deepen their analysis to investigate their role in metastatic process and include the molecular characterization in the clinical practice. In the future, CTCs will be helpful in monitoring patients during treatment, as well as to better address therapeutic strategies.
乳腺癌(BC)是一种在形态学、基因组和遗传水平上具有高度异质性的疾病,即使在同一肿瘤块内或不同患者之间也是如此。因此,不同的亚群共存,而占比少的克隆可能具有选择性优势,这对BC患者的预后有显著影响。循环肿瘤细胞(CTC)是一种罕见的细胞群体,在转移级联反应中起关键作用,近年来,作为一种“液体活检”,它成为克服异质性问题的一个引人关注的选择。然而,除了在晚期上皮性肿瘤中对这些细胞进行原始计数外,临床实践中尚未应用基于CTC的检测方法来改善个性化医疗。在本综述中,我们报告了CTC领域在揭示BC肿瘤内异质性方面的最新发现,支持有必要深入分析CTC以研究其在转移过程中的作用,并将分子特征纳入临床实践。未来,CTC将有助于在治疗期间监测患者,以及更好地制定治疗策略。